Skip to main content

Advertisement

SpringerLink
Log in

Pathogenesis of Chagas Disease: an Emphasis for Transplant Patient Populations

  • Chagas (M Nolan, Section Editor)
  • Published:
Current Tropical Medicine Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Chagas disease is a neglected tropical disease that affects millions of people in the Americas. Reactivation of the infection can occur in the immunosuppressed host, often after organ transplantation. This article aims to review the pathogenesis of Chagas disease with special emphasis on transplant populations in an effort to inform clinicians about the potential risk for reactivation of Chagas disease in high-risk populations.

Recent Findings

Reactivation of Chagas disease is most common in the recipient who had Chagas cardiomyopathy and least common in the recipient of non-heart tissues from Chagas patients. T cell suppression associated with AIDS and transplantation is a major risk factor for reactivation. Certain drugs are associated with a higher risk for reactivation post-transplant, such as mycophenolate motefil. TNF-α inhibitors may also be associated with reactivation of Chagas disease. Routine PCR after transplantation seems to be an adequate tool for early diagnosis after transplant.

Summary

Transplant physicians should be aware of Chagas disease as a potential transmission risk for donors originating from endemic areas. The highest transmission risk being in cardiac donors and lesser risk for liver and kidney donors. Standardized monitoring protocols seem to detect the infection early, reducing the risk for complications from reactivation of Chagas disease in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–402.

    Article  PubMed  Google Scholar 

  2. Chagas Disease (American trypanosomiasis): Epidemiology. World Health Organization. 2018. http://www.who.int/chagas/epidemiology/en/. Accessed 1 Oct 2018.

  3. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:e52–4.

    Article  PubMed  Google Scholar 

  4. • Requena-Méndez A, Aldasoro E, de Lazzari E, Sicuri E, Brown M, Moore DA, et al. Prevalence of Chagas disease in Latin-American migrants living in Europe: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2015;9:e0003540. https://doi.org/10.1371/journal.pntd.0003540 Nice baseline epidemiological study of the prevalence of Chagas in Europe to estimate the burden of disease at a continent level.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Requena-Méndez A, Albajar-Viñas P, Angheben A, Chiodini P, Gascon J, Munoz J, et al. Health policies to control Chagas disease transmission in European countries. PLoS Negl Trop Dis. 2014;8:e3245.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Requena-Méndez A, Bussion S, Aldasoro E, Jackson Y, Angheben A, Moore D, et al. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis. Lancet Glob Health. 2017;5:e439–47.

    Article  PubMed  Google Scholar 

  7. Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the burden of Chagas disease in the United States. PLoS Negl Trop Dis. 2016;10:e0005033. https://doi.org/10.1371/journal.pntd.0005033.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Nóbrega AA, Garcia MH, Tatto E, Obara MT, Costa E, Sobel J, et al. Oral transmission of Chagas disease by consumption of acai palm fruit. Brazil Emerg Infect Dis. 2009;15:653–5.

    Article  PubMed  Google Scholar 

  9. Santos VRCD, Meis J, Savino W, Andrade JAA, Vieira JRDS, Coura JR, et al. Acute Chagas disease in the state of Pará, Amazon region: is it increasing? Mem Inst Oswaldo Cruz. 2018;113:e170298. https://doi.org/10.1590/0074-02760170298.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Coura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmissions—a comprehensive review. Mem Inst Oswaldo Cruz. 2015;110:277–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Noya BA, Pérez-Chacón G, Díaz-Bello Z, Dickson S, Muñoz-Calderón A, Hernández C, et al. Description of an oral Chagas disease outbreak in Venezuela, including a vertically transmitted case. Mem Inst Oswaldo Cruz. 2017;112:569–71.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Filigheddu MT, Górgolas M, Ramos JM. Orally-transmitted Chagas disease. Med Clin (Barc). 2017;148:125–31.

    Article  Google Scholar 

  13. Bern C. Chagas' disease. N Engl J Med. 2015;373:456–66.

    Article  CAS  PubMed  Google Scholar 

  14. Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R, et al. Benznidazole and Posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. J Am Coll Cardiol. 2017;69:939–47.

    Article  CAS  PubMed  Google Scholar 

  15. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, et al. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med. 2015;373:1295–306.

    Article  CAS  PubMed  Google Scholar 

  16. Cucunubá ZM, Okuwoga O, Basáñez MG, Nouvellet P. Increased mortality attributed to Chagas disease: a systematic review and meta-analysis. Parasit Vectors. 2016;27:9–42.

    Google Scholar 

  17. Chin-Hong PV, Schwartz BS, Bern C, Montegomery SP, Kontak S, Kubak B, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: recommendations from the Chagas in Transplant Working Group. Am J Transplant. 2011;11:672–80.

    Article  CAS  PubMed  Google Scholar 

  18. Fiorelli AI, Santos RH, Oliveira JL Jr, Lourenco-Filho DD, Dias RR, Oliveira AS, et al. Heart transplantation in 107 cases of Chagas’ disease. Transplant Proc. 2011;43:220–4.

    Article  CAS  PubMed  Google Scholar 

  19. Kransdorf EP, Czer LS, Luthringer DJ, Patel JK, Montgomery SP, Velleca A, et al. Heart transplantation for Chagas cardiomyopathy in the United States. Am J Transplant. 2013;13(12):3262–8.

    Article  CAS  PubMed  Google Scholar 

  20. Kayama H, Takeda K. The innate immune response to Trypanosoma cruzi infection. Microbes Infect. 2010;12:511–7. https://doi.org/10.1016/j.micinf.2010.03.005.

    Article  CAS  PubMed  Google Scholar 

  21. •• Acevedo GR, Girard MC, Gómez KA. The unsolved jigsaw puzzle of the immune response in Chagas disease. Front Immunol. 2018;9:1929. https://doi.org/10.3389/fimmu.2018.01929 One of the best extensive detailed review on the immunopathogenesis of T. cruzi infection to date.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Vallejo A, Monge-Maillo B, Gutiérrez C, Norman FF, López-Vélez R, Pérez-Molina JA. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease. Acta Trop. 2016;164:117–24.

    Article  CAS  PubMed  Google Scholar 

  23. Linhares-Lacerda L, Granato A, Gomes-Neto JF, Conde L, Freire-de-Lima L, de Freitas EO, et al. Circulating plasma microRNA-208a as potential biomarker of chronic indeterminate phase of Chagas disease. Front Microbiol. 2018;9:269.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Dóka G, Radik M, Krenek P, Kyselovic J, Klimas J. Microrna-208a and its host gene cardiac myosin heavy chain Myh6 are involved in hypertrophic heart dysfunction. J Hypertens. 2015;33:e1. https://doi.org/10.1097/01.hjh.0000467352.59037.c9.

    Article  Google Scholar 

  25. Tarleton RL. CD8+ T cells in Trypanosoma cruzi infection. Semin Immunopathol. 2015;37:233–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lasso P, Mateus J, Pavia P, Rosas F, Roa N, Thomas MC, et al. Inhibitory receptor expression on CD8+ T cells is linked to functional responses against Trypanosoma cruzi antigens in chronic Chagasic patients. J Immunol. 2015;195:3748–58.

    Article  CAS  PubMed  Google Scholar 

  27. Mateus J, Perez-Anton E, Lasso P, Egui A, Roa N, Carrilero B, et al. Antiparasitic treatment induces an improved CD8+ T cell response in chronic Chagasic patients. J Immunol. 2017;198:3170–80.

    Article  CAS  PubMed  Google Scholar 

  28. •• Pérez-Antón E, Egui A, Thomas MC, Puerta CJ, González JM, Cuéllar A, et al. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients. PLoS Negl Trop Dis. 2018;12:e0006480. https://doi.org/10.1371/journal.pntd.0006480 This study provides evidence that benznidazole impact the function of the T cells in patients with chronic Chagas disease suggesting that the treatment effect may immunoregulate the response against T. cruzi infection.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tosello Boari J, Araujo Furlan CL, Fiocca Vernengo F, Rodriguez C, Ramello MC, Amezcua Vesely MC, et al. IL-17RA-signaling modulates CD8+ T cell survival and exhaustion during Trypanosoma cruzi infection. Front Immunol. 2018;9:2347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Reis PG, Ayo CM, de Mattos LC, Brandão de Mattos CC, Sakita KM, de Moraes AG, et al. Genetic polymorphisms of IL17 and Chagas disease in the south and southeast of Brazil. J Immunol Res. 2017. https://doi.org/10.1155/2017/1017621.

  31. De Alba-Alvarado M, Salazar-Schettino PM, Jiménez-Álvarez L, Cabrera-Bravo M, García-Sancho C, Zenteno E, et al. Th-17 cytokines are associated with severity of Trypanosoma cruzi chronic infection in pediatric patients from endemic areas of Mexico. Acta Trop. 2018;178:134–41.

    Article  CAS  PubMed  Google Scholar 

  32. Zingales B. Trypanosoma cruzi genetic diversity: something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop. 2018;184:38–52.

    Article  CAS  PubMed  Google Scholar 

  33. Brenière SF, Waleckx E, Barnabé C. Over six thousand Trypanosoma cruzi strains classified into discrete typing units (DTUs): attempt at an inventory. PLoS Negl Trop Dis. 2016;10:e0004792. https://doi.org/10.1371/journal.pntd.0004792.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Galvao LM, Nunes RM, Cançado JR, Brener Z, Krettli AU. Lytic antibody titer as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg. 1993;87:220–3.

    Article  CAS  PubMed  Google Scholar 

  35. Ramírez JD, Guhl F, Messenger LA, Lewis MD, Montilla M, Cucunuba Z, et al. Contemporary cryptic sexuality in Trypanosoma cruzi. Mol Ecol. 2012;21:4216–26.

    Article  PubMed  Google Scholar 

  36. Vago AR, Andrade LO, Leite AA, d'Avila Reis D, Macedo AM, Adad SJ, et al. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. Am J Pathol. 2000;156:1805–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Burgos JM, Begher S, Silva HM, Bisio M, Duffy T, Levin MJ, et al. Molecular identification of Trypanosoma cruzi I tropism for central nervous system in Chagas reactivation due to AIDS. Am J Trop Med Hyg. 2008;78:294–7.

    Article  CAS  PubMed  Google Scholar 

  38. Messenger LA, Miles MA, Bern C. Between a rock and a hard place: Trypanosoma cruzi genetic diversity and the clinical outcomes of Chagas disease. Expert Rev Anti Ther. 2015;13:995–1029.

    Article  CAS  Google Scholar 

  39. Pirard M, Iihoshi N, Boelaert M, Basanta P, López F, Van der Stuyft P. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion. 2005;45:554–61.

    Article  PubMed  Google Scholar 

  40. Lattes R, Lasala MB. Chagas disease in the immunosuppressed patient. Clin Microbiol Infect. 2014;20:300–9.

    Article  CAS  PubMed  Google Scholar 

  41. Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391:82–94.

    Article  PubMed  Google Scholar 

  42. Gomez CA, Banaei N. Trypanosoma cruzi reactivation in the brain. N Engl J Med. 2018;378:1824.

    Article  PubMed  Google Scholar 

  43. Vacas AS, Gomez-Santana LV, Torre AC, Galimberti RL. Reactivation of Chagas-Mazza disease during treatment with infliximab. An Bras Dermatol. 2017;92:899–900.

    Article  PubMed  Google Scholar 

  44. Kohl S, Pickering LK, Frankel LS, Yaeger RG. Reactivation of Chagas’ disease during therapy of acute lymphocytic leukemia. Cancer. 1982;50:827–8.

    Article  CAS  PubMed  Google Scholar 

  45. Burgos LG, Ortiz BD, Canese A, Ojeda A, Melo M. Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case. Am J Dermatopathol. 2012;34:e84–9.

    Article  PubMed  Google Scholar 

  46. Cossermelli W, Friedman H, Pastor EH, Nobre MR, Manzione A, Camargo ME, et al. Polymyositis in Chagas's disease. Ann Rheum Dis. 1978;37:277–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Del Castillo M, Mendoza G, Oviedo J, Perez Bianco RP, Anselmo AE, Silva M. AIDS and Chagas' disease with central nervous system tumor-like lesion. Am J Med. 1990;88:693–4.

    Article  PubMed  Google Scholar 

  48. Ferreira MS, Nishioka Sde A, Silvestre MT, Borges AS, Nunes-Araújo FR, Rocha A. Reactivation of Chagas’ disease in patients with AIDS: report of three new cases and review of the literature. Clin Infect Dis. 1997;25:1397–400.

    Article  CAS  PubMed  Google Scholar 

  49. Gluckstein D, Ciferri F, Ruskin J. Chagas’ disease: another cause of cerebral mass in the acquired immunodeficiency syndrome. Am J Med. 1992;92:429–32.

    Article  CAS  PubMed  Google Scholar 

  50. Sartori AM, Ibrahim KY, Nunes Westphalen EV, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol. 2007;101:31–50.

    Article  CAS  PubMed  Google Scholar 

  51. Almeida EA, Ramos Junior AN, Correia D, Shikanai-Yasuda MA. Co-infection Trypanosoma cruzi/HIV: systematic review (1980–2010). Rev Soc Bras Med Trop. 2011;44:762–70.

    Article  PubMed  Google Scholar 

  52. Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis. 2012;25:450–7.

    Article  CAS  PubMed  Google Scholar 

  53. Fernandes HJ, Barbosa LO, Machado TS, Campos JP, Moura AS. Meningoencephalitis caused by reactivation of Chagas disease in patient without known immunosuppression. Am J Trop Med Hyg. 2017;96:292–4.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Benatti RD, Oliveira GH, Bacal F. Heart transplantation for Chagas cardiomyopathy. J Heart Lung Transplant. 2017;36:597–603.

    Article  PubMed  Google Scholar 

  55. Bacal F, Silva CP, Pires PV, Mangini S, Fiorelli AI, Stolf NG, et al. Transplantation for Chagas’ disease: an overview of immunosuppression and reactivation in the last two decades. Clin Transpl. 2010;24:E29–34.

    Article  Google Scholar 

  56. •• Gray EB, La Hoz RM, Green JS, Vikram HR, Benedict T, Rivera H, et al. Reactivation of Chagas disease among heart transplant recipients in the United States, 2012–2016. Transpl Infect Dis. 2018;20:e12996. https://doi.org/10.1111/tid.12996 This study uses an effective approach to diagnose Chagas reactivation after transplant before symptoms developed.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Kransdorf EP, Zakowski PC, Kobashigawa JA. Chagas disease in solid organ and heart transplantation. Curr Opin Infect Dis. 2014;27:418–24.

    Article  PubMed  Google Scholar 

  58. • Herwaldt BL, Dougherty CP, Allen CK, et al. Characteristics of patients for whom benznidazole was released through the CDC-sponsored investigational new drug Program for treatment of Chagas disease—United States, 2011–2018. MMWR Morb Mortal Wkly Rep. 2018. https://doi.org/10.15585/mmwr.mm6729a3 Review of benznidazole treatment in the US by CDC prior FDA-approval of the drug. Clinicians should be aware of the commercially availability of this drug in the US.

  59. de Freitas VL, da Silva SC, Sartori AM, Bezerra RC, Westphalen EV, Molina TD, et al. Real-time PCR in HIV/Trypanosoma cruzi coinfection with and without Chagas disease reactivation: association with HIV viral load and CD4 level. PLoS Negl Trop Dis. 2011;5:e1277. https://doi.org/10.1371/journal.pntd.0001277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Balderramo D, Bonisconti F, Alcaraz A, Giordano E, Sánchez A, Barrabino M, et al. Chagas disease and liver transplantation: experience in Argentina using real-time quantitative PCR for early detection and treatment. Transpl Infect Dis. 2017;19. https://doi.org/10.1111/tid.12782.

  61. • Benvenuti LA, Roggério A, Cavalcanti MM, Nishiya AS, Levi JE. An autopsy-based study of Trypanosoma cruzi persistence in organs of chronic chagasic patients and its relevance for transplantation. Transpl Infect Dis. 2017:19. doi: https://doi.org/10.1111/tid.12783. This study shows that solid organs (aside from the heart) of T. cruzi -infected donors can be used for transplantation. However, a close monitoring for reactivation should be followed by the clinician.

  62. Salvador F, Sánchez-Montalvá A, Sulleiro E, Berastegui C, Jauregui A, Pont T, et al. Case report: successful lung transplantation from a donor seropositive for Trypanosoma cruzi infection (Chagas disease) to a seronegative recipient. Am J Trop Med Hyg. 2017;97:1147–50.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Cardillo F, de Pinho RT, Antas PR, Mengel J. Immunity and immune modulation in Trypanosoma cruzi infection. Pathog Dis. 2015;73. https://doi.org/10.1093/femspd/ftv082.

  64. Nihei J, Cardillo F, Dos Santos WL, Pontes-de-Carvalho L, Mengel J. Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi. Eur J Microbiol Immunol (Bp). 2014;4:128–37.

    Article  CAS  Google Scholar 

  65. Pereira IR, Vilar-Pereira G, Marques V, da Silva AA, Caetano B, Moreira OC, et al. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog. 2015;11:e1004594. https://doi.org/10.1371/journal.ppat.1004594.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, Stony Brook University, Stony Brook, NY, USA

    Kalie Smith & Luis A. Marcos

Authors
  1. Kalie Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis A. Marcos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis A. Marcos.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Chagas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smith, K., Marcos, L.A. Pathogenesis of Chagas Disease: an Emphasis for Transplant Patient Populations. Curr Trop Med Rep 6, 1–7 (2019). https://doi.org/10.1007/s40475-019-0168-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40475-019-0168-8

Keywords

Search

Navigation